Virax Biolabs Group Limited (VRAX) Stock Price, Quote & News

Company Profile

Virax Biolabs Group Limited, a biotechnology company, distributes diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of T cell in Vitro Diagnostics. The company offers various in-vitro diagnostics test kits comprising respiratory, pregnancy and fertility, infectious diseases, sti, drugs of abuse, oncology, cardiac, women's health, other test kits under the ViraxClear brands; and rapid and molecular tests for small animal veterinary...

Industry: Biotechnology

Sector: Healthcare

Phone: 44 20 7788 7414

Website: viraxbiolabs.com

Address:

BioCity Glasgow, Bo’Ness Road Newhouse, Lanarkshire, United Kingdom

MichaelHarding605 Jul. 3 at 8:37 PM

$VRAX not chasing here, but the tape deserves respect. Strong move, and once a small-cap starts catching momentum, it can keep running if volume holds. Watching for continuation, not trying to predict the top.

0 · Reply

topstockalerts Jul. 3 at 8:09 PM

$VRAX not chasing, but definitely respecting the move

0 · Reply

WallStreetPulse Jul. 3 at 3:30 PM

$VRAX CEO James Foster on ViraxImmune™: a blood-based immune function test targeting Long COVID, ME/CFS, and post-acute infection syndromes. This is the kind of setup traders watch for in small-cap biotech: a clear unmet need, a differentiated test, and a story built around immune dysfunction rather than broad symptom management.

0 · Reply

MTRADe_01 Jul. 3 at 5:35 AM

$VRAX One of the lowest floats on my watchlist. ~728K float and only ~$2.5M market cap. These are the types that can move fast when volume hits. Watching closely for confirmation before getting aggressive. 👀

0 · Reply

The_Baba_Yaga Jul. 2 at 11:28 PM

$VRAX Going to continue adding this, I know one day I’ll just wake up to 159% one morning. I like my odds here 📈

1 · Reply

The_Baba_Yaga Jul. 2 at 10:25 PM

$VRAX I don’t think people realize how thin this one trades. Too many reasons to be bullish here IMO

0 · Reply

The_Baba_Yaga Jul. 2 at 9:35 PM

$VRAX No signs of active dilution based on the latest public filings, and that’s what continues to amaze me. With a float of roughly 780K shares, this thing is incredibly thin. Add the growing headlines around Bird Flu and Ebola, and it truly wouldn’t take much buying pressure to send this one flying.

2 · Reply

J3_16 Jul. 2 at 9:10 PM

$VRAX Plus the recent cash estimate here is $5 million whereas the market cap is less than half of that. Fair value here after this RS is probably around $20.

0 · Reply

The_Baba_Yaga Jul. 2 at 9:10 PM

$VRAX We have many reasons for high conviction here. Even excluding the obvious, it’s a 780k float and low SS’s

0 · Reply

J3_16 Jul. 2 at 9:09 PM

$VRAX Don't forget the recent spread of Bird Flu over the last few days. Bird Flu is now spread to every continent including Australia. VRAX also has FDA approved products for Bird Flu

0 · Reply

Virax Biolabs Group Ltd trading halted, news pending

2026-06-24T13:05:25.000Z - 10 days ago

Virax Biolabs approves share consolidation program

Jun 24, 2026, 9:00 AM EDT - 10 days ago

Virax Biolabs Group Limited Announces 1-for-25 Share Consolidation

2026-05-26T13:04:03.000Z - 5 weeks ago

Virax Biolabs reports pilot data for ViraxImmune in Long COVID

May 26, 2026, 7:30 AM EDT - 5 weeks ago

Virax Biolabs Reports Positive Early Clinical Data for ViraxImmune™ in Long COVID and Related Post-Acute Infection Syndromes

2026-04-14T11:58:17.000Z - 2 months ago

Virax Biolabs CEO outlines strategic priorities, near-term milestones

Apr 14, 2026, 7:34 AM EDT - 2 months ago

Virax Biolabs' CEO James Foster Outlines Strategic Priorities and Near-Term Milestones in Letter to Shareholders

Mar 31, 2026, 7:34 AM EDT - 3 months ago

Virax Biolabs Achieves ISO Certifications, Laying Foundation for Regulated IVD Development and U.S. Clinical Validation

2026-01-09T17:26:12.000Z - 6 months ago

Virax Biolabs price target lowered to $1 from $3 at H.C. Wainwright

2025-12-18T21:15:19.000Z - 7 months ago

Virax Biolabs files to sell 25.875M ordinary shares for holders

Dec 4, 2025, 4:05 PM EST - 7 months ago

Virax Biolabs Group Limited Announces Closing of $5 Million Private Placement

Dec 3, 2025, 1:53 PM EST - 7 months ago

Virax Biolabs Group Limited Announces $5 Million Private Placement

2025-12-03T13:54:57.000Z - 7 months ago

Why Is Virax Biolabs (VRAX) Stock Rocketing Higher Today?

Dec 3, 2025, 7:34 AM EST - 7 months ago

Virax Biolabs' CEO James Foster Outlines Clinical Progress and 2026 Priorities in Latest Annual Letter to Shareholders

2025-11-03T13:36:20.000Z - 8 months ago

Virax completes patient recruitment for its clinical study evaluating ViraxImmun

Nov 3, 2025, 8:29 AM EST - 8 months ago

Virax Biolabs Completes UK Clinical Recruitment and Reports Constructive FDA Feedback for ViraxImmune™ Study Evaluating T Cell Dysfunction in Post-Acute Infection Syndromes

2025-08-26T11:35:28.000Z - 11 months ago

Virax Biolabs partners with Emory University on ViraxImmune clinical studies

Aug 26, 2025, 7:30 AM EDT - 11 months ago

Virax Biolabs Partners with Emory University on ViraxImmune™ Clinical Studies; Readies for FDA Pre-Submission Meeting in Early September

Jul 29, 2025, 7:35 AM EDT - 1 year ago

Virax Biolabs Appoints Iain Miller, PhD as Independent Director to Accelerate Commercial Strategy

2025-07-19T02:25:41.000Z - 1 year ago

Virax Biolabs receives noncompliance notice from Nasdaq

Jul 18, 2025, 4:15 PM EDT - 1 year ago

Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price Deficiency

2025-03-31T10:15:46.000Z - 1 year ago

Virax Biolabs initiated with a Buy at H.C. Wainwright

2025-03-18T11:36:57.000Z - 1 year ago

Virax Biolabs enrolls first patients in T-cell dysfunction study

Mar 18, 2025, 7:30 AM EDT - 1 year ago

Virax Biolabs Enrolls First Patients in Clinical Study Assessing T cell Dysfunction in Post-acute Infection Syndromes

Mar 13, 2025, 7:30 AM EDT - 1 year ago

Virax Biolabs Presents Data on T-Cell Dysfunction in Post-acute Infection Syndromes at the 19th World Immune Regulation Meeting

Mar 5, 2025, 7:30 AM EST - 1 year ago

Virax Biolabs to Present at 19th World Immune Regulation Meeting

Feb 25, 2025, 7:00 AM EST - 1 year ago

Virax Biolabs Believes Technology Aligns with United States Department of Health and Human Services' Transparency Priority on Vaccine Efficacy

Jan 23, 2025, 3:35 PM EST - 1 year ago

Cosmos Health Signs Expanded Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Saudi Arabia, the UAE, Qatar, and Kuwait

COSM

2025-01-13T14:41:05.000Z - 1 year ago

Cosmos Health secures exclusive distribution agreement with Virax Biolabs

COSM

Jan 13, 2025, 9:20 AM EST - 1 year ago

Cosmos Health Secures Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Greece and Cyprus, with Additional Rights in Select European and GCC Countries

COSM

Dec 17, 2024, 7:30 AM EST - 1 year ago

Virax Biolabs' CEO James Foster Issues Letter to Shareholders

2024-12-10T12:35:42.000Z - 1 year ago

Virax Biolabs enters non-exclusive distribution agreement with Tebubio

Dec 10, 2024, 7:30 AM EST - 1 year ago

Virax Biolabs Announces Agreement with Tebubio to Expand Distribution of ImmuneSelect Across the European Union, Norway, and Switzerland

2024-10-23T11:35:15.000Z - 1 year ago

Virax Biolabs announces distribution agreement with Europa Biosite

Oct 23, 2024, 7:30 AM EDT - 1 year ago

Virax Biolabs Announces Distribution Agreement with Europa Biosite to Commercialize ImmuneSelect in the United Kingdom and Ireland

2024-09-23T13:20:29.000Z - 1 year ago

Cosmos Health enters exclusivity agreement with Virax Biolabs

COSM

2024-09-16T12:50:07.000Z - 1 year ago

Cosmos Health secures exclusivity agreement with Virax Biolabs

COSM

Sep 16, 2024, 8:30 AM EDT - 1 year ago

Cosmos Health Secures Exclusivity Agreement with Virax Biolabs to Distribute mpox PCR Kits across the GCC, including the UAE, Saudi Arabia, Bahrain, Kuwait, Oman, and Qatar

COSM

Sep 16, 2024, 8:30 AM EDT - 1 year ago

Virax Biolabs Announces Extension of Existing Exclusive Distribution Agreement to Market Mpox (formerly Monkeypox) Virus Real-Time PCR Detection Kits with Cosmos Health Inc.

COSM

Sep 9, 2024, 8:00 AM EDT - 1 year ago

Virax Biolabs Presents at H.C. Wainwright's 26th Annual Global Investment Conference

Aug 29, 2024, 9:03 AM EDT - 2 years ago

Virax Biolabs to Participate at 7th European Congress of Immunology

Aug 28, 2024, 2:18 PM EDT - 2 years ago

Virax Biolabs stock soars 45% on Mpox detection kit deal: What you need to know

Aug 28, 2024, 7:30 AM EDT - 2 years ago

Virax Biolabs Announces Distribution Agreement to Commercialize Mpox (formerly Monkeypox) Virus RT-PCR Detection Kits in Europe and the Middle East

2024-08-26T14:15:31.000Z - 2 years ago

Virax Biolabs Group Ltd trading resumes

Aug 23, 2024, 4:09 PM EDT - 2 years ago

Virax Biolabs Group Limited Announces Closing of $5 Million Registered Direct Offering of Ordinary Shares

Aug 21, 2024, 9:30 PM EDT - 2 years ago

Virax Biolabs Group Limited Announces $5 Million Registered Direct Offering of Ordinary Shares

Aug 21, 2024, 10:20 AM EDT - 2 years ago

Cosmos Health Holds EU Distribution Rights for Virax Biolabs' Mpox (formerly Monkeypox) Virus Real-Time PCR Detection Kits

COSM

Apr 25, 2024, 8:00 AM EDT - 2 years ago

Virax Biolabs Launches Portfolio of Immune Profiling Solutions Evaluating Adaptive Immunity in Post-Viral Syndromes at ESCMID Global 2024

Apr 16, 2024, 7:30 AM EDT - 2 years ago

Virax Biolabs to Participate at ESCMID Global 2024

Dec 21, 2023, 7:30 AM EST - 2 years ago

Virax Biolabs Forges Strategic Research Collaboration with University of Manchester and the Northern Care Alliance Foundation Trust to Enhance Understanding of Immune Responses in COVID Patients

Dec 14, 2023, 7:30 AM EST - 2 years ago

Virax Biolabs Group Limited Announces 1-for-10 Share Consolidation

Sep 12, 2023, 7:30 AM EDT - 3 years ago

Virax Biolabs Group Announces Early-Access Program Launch of Research Use Only ViraxImmune Product and Hosts Webinar

Sep 1, 2023, 7:30 AM EDT - 3 years ago

Virax Biolabs Group Appoints Dr. Nigel McCracken as Chief Operating Officer to Oversee Growth Momentum

Aug 3, 2023, 7:30 AM EDT - 3 years ago

Nasdaq Approves 180-Day Extension for Virax Biolabs Group to Meet Minimum $1 Bid

Jul 18, 2023, 7:30 AM EDT - 3 years ago

Virax Biolabs Group Continues Growth and Expansion with the Addition of Research and Laboratory Facilities

May 4, 2023, 7:30 AM EDT - 3 years ago

Virax Biolabs Group Announces Establishment of Regional Headquarters at Dubai Science Park

Apr 19, 2023, 7:30 AM EDT - 3 years ago

Virax Biolabs Group Limited Has Entered into an Agreement for the Distribution of Marburg Virus PCR Testing Kits

Mar 10, 2023, 5:17 PM EST - 3 years ago

Virax Biolabs Group Limited Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Mar 8, 2023, 8:55 AM EST - 3 years ago

Virax Biolabs Group Limited Announces $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Mar 7, 2023, 7:30 AM EST - 3 years ago

Virax Biolabs Group Limited Introduces Avian Influenza A Virus Real-Time PCR Test Kit

Feb 7, 2023, 9:15 AM EST - 3 years ago

Cosmos Health Announces Initial Purchase Order with Virax Biolabs for the Distribution of COVID-19 and Influenza A+B Antigen Combo Rapid Tests

COSM

Feb 7, 2023, 8:30 AM EST - 3 years ago

Virax Biolabs Group Limited Announces Purchase Order to Launch COVID-19 and Influenza A+B Antigen Combo Rapid Tests with Cosmos Health (NASDAQ:COSM)

COSM

Feb 6, 2023, 4:05 PM EST - 3 years ago

Virax Biolabs to Present at the 2023 BIO CEO & Investor Conference

Jan 4, 2023, 7:30 AM EST - 3 years ago

Virax Biolabs Introduces Human Papillomavirus ("HPV") Test Kit

Dec 6, 2022, 7:30 AM EST - 3 years ago

COVID-19 Rapid Antigen Test Distributed By Virax Biolabs Receives Emergency Use Authorization in the United States

Nov 15, 2022, 7:30 AM EST - 3 years ago

Virax Biolabs Appoints Richard Pallin as the Vice President of In Vitro Diagnostic Sales

Nov 8, 2022, 4:30 PM EST - 3 years ago

Virax Biolabs Group Limited Announces Closing of $3.8 Million Private Placement

Nov 4, 2022, 7:30 AM EDT - 3 years ago

Virax Biolabs Group Limited Announces $3.8 Million Private Placement

MichaelHarding605 Jul. 3 at 8:37 PM

0 · Reply

topstockalerts Jul. 3 at 8:09 PM

$VRAX not chasing, but definitely respecting the move

0 · Reply

WallStreetPulse Jul. 3 at 3:30 PM

0 · Reply

MTRADe_01 Jul. 3 at 5:35 AM

0 · Reply

The_Baba_Yaga Jul. 2 at 11:28 PM

$VRAX Going to continue adding this, I know one day I’ll just wake up to 159% one morning. I like my odds here 📈

1 · Reply

The_Baba_Yaga Jul. 2 at 10:25 PM

$VRAX I don’t think people realize how thin this one trades. Too many reasons to be bullish here IMO

0 · Reply

The_Baba_Yaga Jul. 2 at 9:35 PM

2 · Reply

J3_16 Jul. 2 at 9:10 PM

$VRAX Plus the recent cash estimate here is $5 million whereas the market cap is less than half of that. Fair value here after this RS is probably around $20.

0 · Reply

The_Baba_Yaga Jul. 2 at 9:10 PM

$VRAX We have many reasons for high conviction here. Even excluding the obvious, it’s a 780k float and low SS’s

0 · Reply

J3_16 Jul. 2 at 9:09 PM

$VRAX Don't forget the recent spread of Bird Flu over the last few days. Bird Flu is now spread to every continent including Australia. VRAX also has FDA approved products for Bird Flu

0 · Reply

The_Baba_Yaga Jul. 2 at 6:32 PM

$VRAX Interesting… This is one those stocks where you wake up and it’s gapped up 300%, the float is 780k by the way, currently $2.89 is cheap IMO

0 · Reply

StreakGeek Jul. 2 at 4:56 PM

$VRAX $RUBI watchlist

0 · Reply

GrowthVision Jul. 2 at 3:39 PM

$VRAX early pilot data supports ViraxImmune™. Big unmet need here with ~21M Americans affected by post-acute infection syndromes and no widely adopted test yet. U.S. LDT launch is still a 2027 story, so this is more of a long runway setup than a near-term catalyst.

0 · Reply

Jace33 Jul. 2 at 3:01 PM

$VRAX Gimme dat volume!!!

0 · Reply

OliwierS Jul. 2 at 9:16 AM

$VRAX What will surprise us today?

1 · Reply

KobeTheGoat Jul. 1 at 8:06 PM

$VRAX Good luck with that Covid news lol...is covid even a thing anymore? how can you make money on a covid product? seems like a real winner here....Impressive chart straight down for over a year into a reverse split...always epic signs of a real winner. nasty tactics to try and trick investors...sad truth is, this whole board and stock is a bunch of bag holders from way over $4 a share, PRE REVERSE SPLIT....THIS IS A SCAM! ceo a con good luck :-)

2 · Reply

MillionaireTrader555 Jul. 1 at 7:03 PM

$XTLB looking for $3+ $JEM we’ll see if it pops $VRAX we are all waiting on post reverse split biotech news $SDOT just wow 🤯

1 · Reply

F74 Jul. 1 at 6:13 PM

$VRAX What catalysts do they have in the short term? The low floating one is ok but something is needed to trigger the spark.

0 · Reply

MarketsParadise Jul. 1 at 5:17 PM

Small caps heating up, We are seeing some big runners lately. Take a look at ticker DRCT 💎 I believe this is the next monster runner waiting to be found: DRCT 💎 • 600K share float! • AI-powered digital advertising & marketing drive. • Extremely thin chart. • Any sustained buying pressure we look for the 5$+. $VRAX $YYGH $VMAR $CVKD .15

0 · Reply

MillionaireTrader555 Jul. 1 at 4:49 PM

$VRAX $XTLB which one will be the next to explode like $JEM and $SDOT ????

0 · Reply

daytrader11345 Jul. 1 at 3:59 PM

$VRAX scam

1 · Reply

MillionaireTrader555 Jul. 1 at 2:29 PM

$VRAX I hope the PR is after hours so this low floater can explode without halts

1 · Reply

Market Cap	544,000.00
Revenue (ttm)	10,000.00
Net Income (ttm)	-6.06M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-60,600.00%
Debt to Equity Ratio	0.04

Volume	253,600
Avg Vol	985,086
Day's Range	N/A - N/A
Shares Out	174,000.00
Stochastic %K	26%
Beta	1.35
Analysts	Sell
Price Target	$25.00